# Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

> **NCT02207439** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 18 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nelfinavir (Viracept®) 1250 mg
- **OTHER:** Chemoradiation

## Key facts

- **NCT ID:** NCT02207439
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2021-05
- **Final completion:** 2022-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207439, "Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT02207439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*